Additionally, this paradigm-shifting evidence about aP2 biology underscores the potential for designing novel therapeutics based on anti-aP2 monoclonal antibodies (mAb) and offers potential solutions to the existing challenges in diabetes treatment (16). The gene discussed is FABP4; the disease is diabetes mellitus.